Keyword: Sanofi

The Medicines Company announced long-term data for inclisiran, showing that the drug lowered “bad” LDL cholesterol by more than 50%.

The IPO will bankroll a trio of assets through the clinic, including two for complications of diabetes and one for galactosemia, a rare genetic disorder.

Shire R&D chief jumps ship to Ironwood spinout; Daiichi taps new CEO; and Kymab nabs new CEO from Merck KGaA.

Over the past year, Sanofi and Alnylam have been retooling their 2014 R&D pact around Alnylam's RNA tech; today, the pair signaled its end.

Sangamo saw its stock on the up this morning after it posted updates to a series of its trials using a new form of gene editing and cell therapies.

NGM Bio gains a Genentech/Lilly vet as R&D chief; Forma nabs a Genentech commercial exec as CEO; and Nimbus builds out its biology and preclinical teams.

Celgene is paying Exscientia $25 million up front in a three-year discovery deal for three programs in oncology and autoimmunity.

Nimbus promoted Jennifer Rocnik, Ph.D., to vice president of biology and Alan Collis, Ph.D., will serve as vice president of preclinical development.

Dermira has generated evidence that its treatment for moderate-to-severe atopic dermatitis can pose a challenge to Regeneron and Sanofi’s Dupixent.

Sanofi's CMO takes on chief digital officer role; Parexel nabs four high-profile FDA staffers; and Nimbus poaches Janssen's discovery head as CSO.